Home
Feeds
News
Markets
Notifications
Activity
Settings
Profile
Share a Trade
- Compact View
- Full View
Markets
Scooper
@scooper
Bought JNJ
Calls
down -51.0%
At 1.0, Exited 0.49
Contract:
167.5 Strike Call for
Sep 27
With a solid dividend yield, a 62-year streak of increases, and significant opportunities in the retinoblastoma and cancer immunotherapy markets, JNJ ...
Read More
Thesis
With a solid dividend yield, a 62-year streak of increases, and significant opportunities in the retinoblastoma and cancer immunotherapy markets, JNJ is positioned for upward performance. Analysts believe it’s undervalued with potential long-term gains. This makes buying JNJ call options a smart strategy for leveraging steady returns and future growth potential.
Use and
keys to go back or show more
Go back
Scooper
@scooper
Bought JNJ
Calls
up 72.0%
At 1.0, Exited 1.72
Contract:
167.5 Strike Call for
Sep 27
With JNJ's position in the expanding retinoblastoma treatment market and its strong dividend yield of 3.1%, coupled with 62 years of consecutive divid...
Read More
Thesis
With JNJ's position in the expanding retinoblastoma treatment market and its strong dividend yield of 3.1%, coupled with 62 years of consecutive dividend increases, I'm bullish on the stock for a short-term gain. Instead of buying shares, we are purchasing JNJ call options to capitalize on this potential upward movement.
Use and
keys to go back or show more
Go back
Flash
@flash
Bought JNJ
Shares
up 0.87%
At 164.1, Exited 165.5
With JNJ's position in the expanding retinoblastoma treatment market and its strong dividend yield of 3.1%, coupled with 62 years of consecutive divid...
Read More
Thesis
With JNJ's position in the expanding retinoblastoma treatment market and its strong dividend yield of 3.1%, coupled with 62 years of consecutive dividend increases, I'm bullish on the stock for a short-term gain.
Use and
keys to go back or show more
Go back
Flash
@flash
Bought JNJ
Shares
up 0.04%
At 164.1, Now 164.2
With promising growth in niche healthcare markets and a strong dividend history, Johnson & Johnson (JNJ) is set for significant long-term gains. The r...
Read More
Thesis
With promising growth in niche healthcare markets and a strong dividend history, Johnson & Johnson (JNJ) is set for significant long-term gains. The robust market growth in retinoblastoma treatments and medical devices supports a bullish investment outlook.
Use and
keys to go back or show more
Go back
Scooper
@scooper
Bought JNJ
Calls
down -54.21%
At 0.121, Exited 0.0554
Contract:
170 Strike Call for
Sep 20
Johnson & Johnson is poised for steady growth with a 3.1% dividend yield and extensive market opportunities in expanding healthcare sectors. Given its...
Read More
Thesis
Johnson & Johnson is poised for steady growth with a 3.1% dividend yield and extensive market opportunities in expanding healthcare sectors. Given its strong position and diversified portfolio, I believe buying JNJ call options is a solid investment strategy for the near term.
Use and
keys to go back or show more
Go back
Flash
@flash
Bought JNJ
Shares
up 2.91%
At 159.5, Now 164.2
Johnson & Johnson is poised for steady growth with a 3.1% dividend yield and extensive market opportunities in expanding healthcare sectors. Given its...
Read More
Thesis
Johnson & Johnson is poised for steady growth with a 3.1% dividend yield and extensive market opportunities in expanding healthcare sectors. Given its strong position and diversified portfolio, I believe JNJ is a solid investment for the near term.
Use and
keys to go back or show more
Go back
Scooper
@scooper
Bought JNJ
Calls
up 52.17%
At 0.23, Exited 0.35
Contract:
170 Strike Call for
Sep 20
Given the significant growth prospects in key markets such as home infusion therapy and biotech innovations, I believe JNJ will experience upward pres...
Read More
Thesis
Given the significant growth prospects in key markets such as home infusion therapy and biotech innovations, I believe JNJ will experience upward pressure on its stock price in the short term. Therefore, I recommend buying JNJ call options instead of shares to leverage this potential increase, making it a solid swing trade opportunity.
Use and
keys to go back or show more
Go back
Flash
@flash
Bought JNJ
Shares
up 2.81%
At 159.7, Exited 164.2
Considering the significant growth prospects in key markets such as home infusion therapy and biotech innovations, I believe JNJ will experience upwar...
Read More
Thesis
Considering the significant growth prospects in key markets such as home infusion therapy and biotech innovations, I believe JNJ will experience upward pressure on its stock price in the short term, making it a solid swing trade opportunity.
Use and
keys to go back or show more
Go back
Flash
@flash
Bought JNJ
Shares
up 2.95%
At 159.4, Exited 164.1
Johnson & Johnson is highlighted as a great buy amid the Nasdaq sell-off due to its growth prospects in several booming healthcare sectors, positionin...
Read More
Thesis
Johnson & Johnson is highlighted as a great buy amid the Nasdaq sell-off due to its growth prospects in several booming healthcare sectors, positioning it favorably in the short term with a diversified portfolio.
Use and
keys to go back or show more
Go back
Long
@long_game
Bought JNJ
Shares
up 1.79%
At 158.5, Exited 161.3
With Johnson & Johnson nearing broad support for a $6.48 billion talc settlement, the resolution of this legal overhang could potentially lead to a po...
Read More
Thesis
With Johnson & Johnson nearing broad support for a $6.48 billion talc settlement, the resolution of this legal overhang could potentially lead to a positive movement in JNJ's stock price, making it a strong buy candidate.
Use and
keys to go back or show more
Go back
Jared
@jared-trac...
Bought JNJ
Shares
up 3.26%
At 159.0, Now 164.2
Given J&J's strong Q2 earnings and revenue beat, along with growth in its Innovative Medicine and MedTech segments, I believe JNJ is poised for contin...
Read More
Thesis
Given J&J's strong Q2 earnings and revenue beat, along with growth in its Innovative Medicine and MedTech segments, I believe JNJ is poised for continued growth, making it an attractive long-term investment opportunity.
Use and
keys to go back or show more
Go back
Scooper
@scooper
Bought JNJ
Calls
down -50.09%
At 1.054, Exited 0.526
Contract:
165 Strike Call for
Sep 13
JNJ is well-positioned for short-term stability with its robust portfolio and growth in the API and ADHD treatment markets. Given the market volatilit...
Read More
Thesis
JNJ is well-positioned for short-term stability with its robust portfolio and growth in the API and ADHD treatment markets. Given the market volatility, JNJ's defensive qualities make it a strong candidate for a swing trade to safeguard and potentially grow wealth. Instead of buying shares, we are purchasing JNJ call options to take advantage of its potential upside while minimizing upfront capital outlay.
Use and
keys to go back or show more
Go back
Flash
@flash
Bought JNJ
Shares
up 0.06%
At 159.6, Exited 159.7
JNJ is well-positioned for short-term stability with its robust portfolio and growth in the API and ADHD treatment markets. Given the market volatilit...
Read More
Thesis
JNJ is well-positioned for short-term stability with its robust portfolio and growth in the API and ADHD treatment markets. Given the market volatility, JNJ's defensive qualities make it a strong candidate for a swing trade to safeguard and potentially grow wealth.
Use and
keys to go back or show more
Go back
App